News
17h
Zacks Investment Research on MSNWill Carvana Continue to Build on Its Cash Flow Strength in 2025?Carvana’s CVNA primary sources of operating cash flows are derived from the sale of retail vehicles, wholesale vehicles, originated loans and complementary products, including vehicle service ...
4d
Zacks Investment Research on MSNCarvana Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?Carvana CVNA is slated to release second-quarter 2025 results on Wednesday, after market close. The Zacks Consensus Estimate ...
Summary. Carvana's stock has shown a 152% year-to-date gain in 2024, making it one of the best-performing stocks. The company successfully transformed from a loss-making entity to a profitable ...
Carvana has received a total of 22 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $338.59, the consensus suggests a potential 0.67% upside.
Carvana's turnaround is remarkable, driven by debt restructuring, cost cuts, margin gains, and a recovering used car market fueling record sales and profits. The digital-first business model ...
Carvana is trading at a forward sales multiple of 2.54X, way above its median of 0.69X, over the last three years. KMX’s forward sales multiple sits at 0.45X, slightly above its median of 0.43X ...
Carvana (NYSE:CVNA), a leading e-commerce platform for buying and selling cars, has released its earnings for the fourth quarter of 2024, detailed on February 19, 2025. The highlight of the ...
Carvana Co. may have spooked investors late Wednesday as the online used-car platform saw a drop in its revenue per vehicle sold retail. Carvana (CVNA) reported fourth-quarter numbers that beat ...
I believe in Carvana, not necessarily as a short-term trading vehicle, but as a long-term investment because I believe in the leadership of CEO Ernie Garcia, who’s created a tremendous amount ...
The revival of Carvana's stock from its 2022 lows has brought a titanic rise in the fortunes of its CEO and his father, ... Virginia Gov. Youngkin on AstraZeneca's $50B investment in the US.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results